Can a new oral drug take on hard-to-treat leukaemia?

NCT ID NCT07723703

Not yet recruiting Disease control Sponsor: Amphista Therapeutics Ltd Source: ClinicalTrials.gov ↗

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This early-stage trial is testing an experimental drug called AMX-883, taken by mouth, for people with acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS) that has come back or not responded to standard treatments. The study will first test AMX-883 alone, then in combination with another drug (posaconazole) in people with AML. The main goals are to check the drug's safety, find the best dose, and get an early look at whether it can help control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental oral drug called AMX-883, sometimes given with the antifungal posaconazole
What this could lead to: If safe and effective, AMX-883 could offer a new treatment option for people with hard-to-treat leukaemia or related blood disorders.
What could go wrong: This is an early phase 1 trial with only 54 participants, focused on safety and dosing. It is too soon to know if the drug will work, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKAEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloblastic leukemia with maturation acute myeloid leukemia myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKAEMIA HIGH RISK MYELODYSPLASTIC SYNDROME

More trials for these conditions

Other studies related to the condition(s) this trial covers.